Matthew T. Campbell, MD, MS

home / authors / matthew-t-campbell-md-ms

Articles

Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

December 19th 2023

Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.

Triple Combination Therapies in RCC: Clinical Trial Insights

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

December 19th 2023

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

December 12th 2023

Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.

Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

December 12th 2023

Expert insight into how to discuss and manage treatment-related toxicities with cancer patients and their families, emphasizing the importance of early communication and vigilance.

Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

December 5th 2023

Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).

Sequencing and Second-Line Therapy in RCC: Patient Scenario

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

December 5th 2023

Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.

Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

November 28th 2023

Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.

Comparing Treatment Combinations in Renal Cell Carcinoma

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

November 28th 2023

A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.

Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

November 21st 2023

Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.

Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

November 21st 2023

Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.

Imaging and Staging Considerations in Renal Cell Carcinoma

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

November 14th 2023

Key opinion leaders discuss the use of brain MRI and bone assessment in the staging and monitoring of patients with renal cell carcinoma.

Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

November 14th 2023

Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.

Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

Ulka Vaishampayan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD;Alan Tan, MD

October 30th 2023

Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.